Deep-vein thrombosis (DVT) is a common condition that can lead to complications such as
postphlebitic syndrome, pulmonary embolism and death. The approach to the diagnosis of …

Therapeutic Plasma Exchange in Refractory VITT Three patients with severe manifestations
of VITT after Covid-19 vaccination had a poor response to initial therapy with anticoagulants …

It has been suggested that a G-to-T transition in exon 2 of the factor XIIIA gene resulting in a
substitution of leucine for valine at amino acid 34 (FXIII Val34Leu) protects against venous …

Introduction Data on efficacy and safety of using low molecular weight heparin in cancer
patients with catheter-related upper extremity deep vein thrombosis is scarce and the risk of …

Background: After a first unprovoked venous thromboembolism (VTE), many patients have
residual pulmonary and/or lower limb vascular obstruction following completion of short‐term …

INTRODUCTION: D-dimer testing is widely used in conjunction with clinical pretest
probability (PTP) for venous thromboembolism (VTE) exclusion. We report on a multicenter …

Background Choosing short-term (3-6 months) or indefinite anticoagulation after a first
unprovoked venous thromboembolic event (VTE) is a common and difficult clinical decision. The …

Genetic factors are thought to contribute to the pathogenesis of acute myocardial infarction (AMI).A
common variant of factor XIII (FXIII), FXIII Val34Leu, may be protective against …

BACKGROUND: Mortality rates due to pulmonary embolism (PE) are difficult to estimate
often due to the presence of comorbid disease. OBJECTIVES: To determine the accuracy of …

Background Controversy exists whether low-dose vitamin K supplementation can improve
anticoagulation control in patients with unstable anticoagulation under warfarin. In a single- …